Palmitoylethanolamide in the Treatment of Pain and Its Clinical Application Prospects
ReviewHumans
- Design
- Review
- What was measured
- What the evidence says about palmitoylethanolamide for pain: mechanisms via PPAR-alpha and the endocannabinoid system, and clinical studies in fibromyalgia, low back pain, chemotherapy-related nerve pain, osteoarthritis, sciatica, pelvic pain and diabetic neuropathy
What the authors reported
Palmitoylethanolamide acts through PPAR-alpha and the endocannabinoid system across multiple targets, with a low rate of adverse reactions, mainly mild gastrointestinal discomfort and dizziness. The authors list the evidence gaps as too few large multi-centre randomised trials, no standard formulation, little long-term follow-up, and unsettled dosing.
Limits of this study
A review, with no pooled analysis. The authors' own list of gaps applies to the evidence it summarises. The work was funded by Chinese public research programs, and the authors declared no conflicts.
Source
Entry checked against the full text at the publisher (Dove Medical Press) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.